What if We Could Find Cancer Sooner?

EDISYN: Early Detection In Syndromic Cancers

The EDISYN Consortium was established to identify new ways to detect cancer in patients with Li-Fraumeni Syndrome and other cancer predisposition syndromes before tumors are large enough to cause symptoms or be detected by imaging.

About

What is EDISYN?

EDISYN was founded to serve a unique population of patients, those with inherited predisposition to cancer, with the goal of advancing techniques of cancer surveillance through scientific exploration. Together, physician-scientists, clinicians, laboratory specialists, genetic counselors, and research coordinators all play unique roles within the organization. In addition, we have partnered closely with leaders of patient advocacy groups strengthening our connection with the community.

Who We are

Dedicated to Improving Cancer Outcomes

EDISYN brings together physician-scientists who have focused clinical and research interest in improving outcomes for patients with Li-Fraumeni Syndrome and other cancer predisposition syndromes. We are partnering with patients who have generously agreed, through participation in research and banking studies, to contribute data and blood samples to develop novel non-invasive liquid biopsy tests that can detect the presence of cancer before it is otherwise detectable.

Participate

Your Samples Drive Research

Recent studies have detected fragments of tumor-derived DNA in the blood of patients with cancer. Sensitive new sequencing technologies have allowed for the detection of “circulating tumor DNA” in the blood of patients with cancer. The EDISYN Consortium is working to combine these new liquid biopsy techniques with genetics in order to detect circulating tumor DNA in persons with cancer predisposition syndromes, such as Li-Fraumeni Syndrome, before displaying clinical symptoms. We believe detecting circulating tumor DNA in asymptomatic individuals will lead to early cancer detection which improves outcomes. Participating in research at one of our participating institutions will allow you to provide the samples we need to create sensitive liquid biopsy assays.

FAQ

Common Questions

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.